Tech Company Financing Transactions
Pionyr Immunotherapeutics Funding Round
Pionyr Immunotherapeutics closed a $275 million financing round on 6/24/2020. Investors included Gilead Sciences.
Transaction Overview
Company Name
Announced On
6/24/2020
Transaction Type
Venture Equity
Amount
$275,000,000
Round
Undisclosed
Investors
Gilead Sciences (Daniel O'Day)
Proceeds Purpose
This agreement underscores the value of our myeloid tuning platform and the potential of our pipeline of antibody therapeutics designed to turbocharge the immune system within the tumor microenvironment.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Tower Pl. 800
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Pionyr develops drugs to perform exceptional fine-tuning of immune responses. This goal addresses a current and justified excitement about immunotherapy and introduces technology to rapidly identify and target novel arms of the immune response, within the tumor microenvironment (TME).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven James
Chief Financial Officer
Monte Montgomery
Chief Medical Officer
Leonard Reyno
Chief Scientific Officer
Michel Streuli
Vice President
Kevin Baker
Vice President
Evan Greger
VP - Bus. Development
Alicia Levey
VP - Operations
Michael Ellis
Browse more venture capital transactions:
Prev: 6/24/2020: Armored Things venture capital transaction
Next: 6/24/2020: Treehouse Games venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs